New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran − Treatment with Vutrisiran Led to 37- 49% Lower Rates of ...
− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac ...
Vutrisiran, a subcutaneous therapy that knocks down transport protein levels in the liver, may lower the risk of death and recurrent CV events in patients who have transthyretin amyloidosis with ...
CAMBRIDGE, Mass., March 29, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from ...
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label ...
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that results from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA ® (vutrisiran), an RNAi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback